Trial Profile

A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 25 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SEphB4-HSA (Primary)
Indications Bladder cancer; Prostate cancer; Renal cancer; Renal cell carcinoma; Urogenital cancer
Focus Adverse reactions

Most Recent Events

15 Nov 2021 Status changed from recruiting to discontinued.
09 Aug 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Jul 2019).
08 Jun 2019 Planned End Date changed from 2 Aug 2020 to 2 Aug 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com